Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Drug Layering in Heart Failure

JACC Heart Failure(2021)10.1016/j.jchf.2021.06.011Source: DataRank Database

Drug Layering in Heart Failure is a research paper published in JACC Heart Failure (2021). On theSindex it has a DataRank of 0. It has been cited 47 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access47 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (22 grants)Impact (FWCI 6.13)OA: bronzeTopics (23)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Larry A. Allen ORCID,Amr Abdin ORCID,JoAnn Lindenfeld ORCID,Eileen O’Meara ORCID,Carolyn S.P. Lam ORCID

Live enrichment

PubMed:34627725 OpenAlex:https://openalex.org/W3204904358

Deutsche Forschungsgemeinschaft

Grant: 322900939

Deutsche Forschungsgemeinschaft

Grant: TTR 219

Deutsche Forschungsgemeinschaft

Grant: unidentified

unidentified

Bayer

Cytokinetics

Patient-Centered Outcomes Research Institute

Servier

AstraZeneca

Amgen

Australian Carbon Innovation

Medtronic

National Institutes of Health

Novartis

Abbott Laboratories

Biotronik

Edwards Lifesciences

Boehringer Ingelheim

Boston Scientific Corporation

Impulse Dynamics

American Heart Association

Pfizer

Roche

FWCI

6.13

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

bronzeLicense: Elsevier Non-Commercial

journalhttps://ars.els-cdn.com/content/image/1-s2.0-S2213177921003267-fx1_lrg.jpg

publisherhttps://ars.els-cdn.com/content/image/1-s2.0-S2213177921003267-fx1_lrg.jpg

publisherhttps://api.elsevier.com/content/article/PII:S2213177921003267?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2213177921003267?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jchf.2021.06.011

Fields of Study

Heart Failure Treatment and ManagementPotassium and Related DisordersDiabetes Treatment and Management03 medical and health sciences0302 clinical medicine

MeSH Terms

Pharmaceutical PreparationsHeart FailureHumansPhenotypeProspective StudiesStroke Volume

Keywords

MedicineHeart failureEjection fractionIntensive care medicineClinical trialInternal medicineBlood pressureCardiologyDrugsPrognosisMedical TreatmentHeart Failure Treatments

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Related Papers (1)

Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy

N/A

1.2DataRank · unranked

European Journal of Heart Failure(2020)

co-cited

10.1002/ejhf.1971